Services on Demand
Print version ISSN 0037-8682
Rev. Soc. Bras. Med. Trop. vol.32 n.3 Uberaba May/June 1999
Serum cytokines in chronic Chagas' disease
Citocinas séricas na forma crônica da doenca de Chagas
Laura S. Ward1, Maria E. Guariento1, Gilberto A. Fernandes2 e Rui M.B. Maciel3
Abstract We studied the serum levels of IL-2, IFN-g and TNF in different clinical forms of Chagas' disease and in patients clinically compensated and decompensated. Cytokines measured in 91 patients with the chronic form of the disease did not differ from those of 13 normal individuals, suggesting the absence of activation of the TH1 pattern of lymphocyte response. There were no statistical differences among the 17 patients in the indeterminate form of the disease, the patients presenting either early (n = 4) or well-developed signs of cardiomyopathy (n = 62), the digestive (n = 4) or the mixed (n = 4) forms of the disease. Serum TNF was undetectable and IFN-g levels did not differ between clinical forms and severities of Chagas' disease. However, we found IL-2 higher levels in the 25 non-controlled patients than in the 66 controlled individuals (p < 0,001). We suggest that IL-2 dosage may be useful as an indicator of the need for more aggressive procedures.
Key-words: Cardiomyopathy. Clinical form. Severity. Cytokines. Chagas' disease.
Resumo Estudamos os níveis séricos da IL-2, IFN-g e do TNF-a de portadores da doença de Chagas em suas diferentes formas clínicas, compensados e descompensados. As citocinas medidas nos 91 pacientes com a forma crônica da doença não diferiram dos níveis de 13 indivíduos controle. Não houve diferença estatística entre os 17 portadores da forma indeterminada da doença e os portadores de cardiopatia insipiente (n = 4), de cardiopatia bem estabelecida (n = 62), da forma digestiva (n = 4) ou da forma mista (n = 4) da doença. Os níveis séricos de TNF foram indetectáveis e IFN-g não diferiu nas diferentes formas clínicas ou com a severidade da doença. No entanto, encontramos níveis mais elevados de IL-2 nos 25 pacientes não-contrololados do que nos 66 pacientes bem compensados (p < 0,001). Sugerimos que a dosagem de IL-2 possa servir como indicadora da necessidade de terapêuticas mais agressivas nestes pacientes.
Palavras-chaves: Miocardiopatia. Forma clínica. Severidade. Citocinas. Doença de Chagas.
Chagas' disease is estimated to affect 18 million people in Brazil6. The disease is one of the most important causes of morbidity and mortality in a broad area ranging from Argentina to the South of the United States16 28. Characteristically, after a self-limited acute phase, the immune response controls parasitism yet fails to completely eradicate the protozoan parasite. It is interesting that in the chronic phase, Chagas' disease becomes clinically manifested in less than 60% of the infected individuals who develop the characteristic cardiac and/or digestive manifestations of the disease17. The heart is the organ most frequently affected, followed by the autonomic nervous system, the lesion of which leads to the digestive form of the disease17. The pathogeny of the disease is still unclear, but three main mechanisms have been proposed for it: the neurogenic, the microvascular and the immunological-autoimmunity theories12 22. The few existing studies of the acute human infection demonstrate an abnormal immunological response to the parasite25 26. Immunologic findings in the chronic phase are more difficult to interpret, particularly considering the different clinical forms of the disease. A series of manifestations of immune-suppression have been demonstrated in experimental animals and in human, but the mechanism by which they develop remains obscure13 20 21 26. Depressed responses were reported in patients with either the cardiac or the digestive form of Chagas' disease although parasite antigen-specific and/or mitogen-induced PBMC proliferative responses were reported to be normal4. Normal levels of NK cell activity and normal IL-2 activated cytotoxicity (LAK) were shown in both symptomatic and non-symptomatic cardiac patients23. On the other hand, NK cell activity was found to be enhanced by in vitro exposure of PBMC to T. cruzi antigen in all but symptomatic patients3. Increased HLA-DR expression by peripheral blood T-cells and a higher frequency of CD28T cells have been described in both symptomatic and indeterminate phase patients but neither IL-2 or IL-4 message in PBMC nor serum IL-2r levels were found to be augmented4 7 8 9.
Because of their well-known actions in the inflammatory response, some investigators have attempted to relate cytokines levels to the severity of diseases10 21 24 27. We and others also demonstrated that chagasic patients with different clinical forms of the disease have peripheral blood mononuclear cells, which respond to T. cruzi antigen with a cytotoxic response that is selectively up regulated by IL-122 3. However, we found no difference in the increment caused by cytokine treatment among the different forms of Chagas' disease2.
In the present study, we have examined some important cytokines levels in patients of chronic Chagas' disease with different clinical forms and severity.
MATERIAL AND METHODS
Controls. The Medical Ethics Committee of the Hospital das Clínicas (FCM/UNICAMP) granted permission to study 20 healthy medical students who volunteered to provide normal parameters for the cytokine assays. After careful clinical examination, a blood sample was obtained from each subject for serum IL-2, IFNg and TNFa determinations. All individuals were observed for a period of four to eight weeks and when they were suspected of any immune or inflammatory disease, their data were eliminated from analysis of the results. At the end of the observation period, only six males and seven females were selected (median age 24 years, range 21 to 27 years) and denoted group N.
Patients. Ninety one Chagas' disease patients were sequentially selected among the individuals who routinely attend the outpatient clinic. After a careful clinical observation and a review of each patient medical records, the subjects were classified as (-) when they had few or no symptoms, i.e., when they did not present manifestations of Chagas' disease and/or of any concomitant pathology, and as (+) when they were symptomatic or in an advanced stage of heart disease (functional type IV by the criteria of the Committee of the American Cardiology Association41. Again we discarded all data from patients suspected of any other concurrent active immune or inflammatory disease.
According to their clinical manifestation of the disease, the patients were divided into:
. Group I (indeterminate form): seventeen patients (8 M, 9 F) aged 21 to 71 years (X = 48 ± 15 years) non-symptomatic, with no cardiac or visceral manifestations, although they had serologic tests confirming Chagas' disease. Eight of these patients had other diagnoses that included asthma (one case), arterial hypertension (four cases), coronary artery disease (two cases) and peptic ulcer (one case), but no one presented clinical manifestations during the period of observation of this study.
. Group II (early cardiac form): four patients (2M, 2F) aged 45 to 58 years (X = 54 ± 10 years) showed abnormalities in the ECG but had normal cardiac function. Although the four had other concomitant diagnosis, including chronic obstructive pulmonary disease and coronary artery disease (two cases each), no one presented clinical manifestations during the observation period.
. Group III (cardiomyopathy): sixty-two patients (20 M, 42F) aged 34 to 71 years (X = 55 ± 8.5 years) with Chagas' cardiac disease. These patients had been using amiodarone to control their arrhythmia at the dose of Mo = 400mg/day for about 4 years (Mo = 4 years). At the time of blood collection, 24 of these patients presented decompensated heart disease with clear clinical manifestations (22 patients were functional type III, and two patients were classified as functional type IV).
. Group IV (digestive form): four patients (1 M, 3F) aged 38 to 62 years (X = 51 ± 13 years) with megaesophagus or megacolon confirmed by radiological examination but no sign of cardiac disease. One of these individuals also had a well-controlled hypertension.
. Group V (mixed form): four patients (4 F) aged 37 to 67 years (X = 54 ± 7 years) with the combined manifestations of groups III + IV. No patient was using amiodarone. One of these individuals presented signs of non-compensated heart disease at the time of blood collection.
Methods. Blood sampling took place between 9:00 and 13:00h. The samples were immediately processed and stored at -20oC until assayed. IL-2, g-IFN and TNF-a were measured by solid-phase enzyme immunoassays employing the multiple antibody sandwich principle (Intertest-2 Human Interleukin-2, Intertest-g Human IFN-g and Predicta Tumor Necrosis Factor-a ELISA kits), obtained from Genzyme Diagnostics, Cambridge, MA, USA. IL-2 kit had a detection limit of 100pg/ml. IFN-g kit also had a detection limit of 100pg/ml. TNF-a detection limit was 10pg/ml.
Statistical analysis. The results are expressed as the mean ± standard error. Since the data did not show a normal distribution, they were analyzed by the Kruskal-Wallis (H statistic) test, the c2 test or Wilcoxon's rank sum test (Z statistic), as appropriate. Statistical analysis that did not reach a level of significance of p < 0.05 were considered as non-significant (NS). For statistical purposes, undetectable cytokine levels were assigned an arbitrary level corresponding to the least detectable value of the method.
Normal individuals did not differ from Chagas' disease patients in terms of age or gender (c2 = NS). There was also no difference among the patients grouped according to their clinical form (I to V) (c2 = NS). The results of both normal individuals and Chagas' disease patients are shown in Table 1. IL-2 levels ranged from 200 to 5120pg/dL, g-IFN ranged from 42 to 190 pg/dL, and TNF was undetectable in all individuals. There was no significant difference in serum cytokine levels between normal individuals and chagasic patients. Analysis of the 91 patients as a whole showed no correlation among IL2, TNF and IFN-g levels. Considering the forms of clinical presentation of the disease, we observed a tendency of IL-2 levels to decrease from group I to group V, while IFN levels were randomly distributed (H = NS for both IL-2 and IFN).
Sixty-six patients did not have concomitant pathologies or were considered to be clinically compensated (-), whereas 25 not controlled were classified as (+). Their serum cytokine levels are presented in Table 2. There was no difference in the IFN-g (Z = 0.74; p = 0.22). However, serum IL-2 levels were higher in the non-controlled patients (Z = 3.895, p < 0.001).
Like many other parasitic infections, T. cruzi induces alteration in the immunological system of the host to circumvent his defense mechanisms10. IL-2, IFN-g and TNF-a probably contribute to the control of parasite growth by triggering phagocytic cell activation and inflammation1. There are also evidences that, in addition to mechanical damage related to the presence of the parasite, infection by T. cruzi induces proinflammatory cytokine production in the myocardium itself, which may further exacerbate the pathology5 12.
Serum cytokine quantification has seldom been reported in Chagas' disease. One major reason for this is the widespread involvement of cytokines in inflammatory responses that may impair the interpretation of serum cytokine levels. In the present investigation, we studied the serum levels of IL-2, IFN-g and TNF in different clinical forms of Chagas' disease. The serum cytokine levels in patients with the chronic form of the disease did not differ from those of normal individuals, suggesting a lack of activation of the TH1 lymphocyte response. Since most of our patients presented the cardiac form of the disease, these results agree with recent experimental studies suggesting that a lower level of TH1 activity may play a role in cardiac involvement, whereas an enhanced TH-1-type response is related to protective immunity and decreased pathogenesis14 18. Serum TNF-a levels were undetectable in both chronic chagasic patients and normal individuals. Serum IFN-g levels also did not differ among clinical forms and the stage of the disease. Variations have been reported between symptomatic versus indeterminate form and in patients with cardiac and indeterminate form. However, cytokine profile does not seem to differentiate the clinical presentations of the disease.
In contrast, serum IL-2 levels were significantly increased in patients with decompensated cardiac function. IL-2 is a glycoprotein of pleotropic effects including the activation and proliferation of T cells, natural killer cells and B cells. Suppression of the IL-2 gene with deficient serum IL-2 and IL-2 receptor expression, apparently mediated by suppressor macrophages, is a well documented phenomenon occurring during acute infection which possibly plays an important role in the evolution of the disease19 28. Nonetheless, its role in Chagas' disease is still poorly understood. It is intriguing to note that IL-2 levels increase strikingly in non-compensated individuals, even though their distribution pattern in the different forms of the disease suggest an inverse correlation with more aggressive forms of the disease (Table 1).
It is frequently difficult to appraise the clinical condition of Chagas' disease patients, because of their misleading autonomic symptoms adjoined by specific social and cultural characteristics. Our results suggest that IL-2 may be related to the severity of the disease. Its increased level in non-compensated patients may be useful a useful tool in the clinical evaluation of these patients as an indicator of the need for more aggressive or invasive procedures.
1. Abrahamsohn IA. Cytokines in innate and acquired immunity to Trypanosoma cruzi infection. Brazilian Journal of Medical and Biological Research 31:117-121, 1998. [ Links ]
2. Barros-Mazon S, Guariento ME, Abrahamsohn IA. IL-2 enhances proliferation of peripheral blood mononuclear cells from Chagas' disease patients to Trypanosoma cruzi antigen. Immunology Letters 57:39-45, 1997. [ Links ]
3. Brodskyn CI, Barral MA, Bulhões MA, Souto T, Machado WC, Barral-Neto M. Cytotoxicity in patients with different clinical forms of Chagas' disease. Clinical Experimental Immunology 105:450-455, 1996. [ Links ]
4. Cetron MS, Basilio FP, Moraes AP, Souza AQ, Paes JN, Kahn SJ, Wener MH, Van Voorhis WC. Humoral and cellular response of adults from northeastern Brazil with chronic Trypanosoma cruzi infection: depressed cellular immune response to T. cruzi antigen among Chagas' disease patients with symptomatic versus indeterminate infection. American Journal of Tropical Medicine and Hygiene 49:370-383, 1993. [ Links ]
5. Chandrasekar B, Melby PC, Troyer DA, Freeman GL. Induction of proinflammatory cytokine expression in experimental acute chagasic cardiomyopathy. Biochemical and Biophysical Research Community 223:365-371, 1996. [ Links ]
6. Dias JCP. A doença de Chagas e seu controle na América Latina. Uma análise de possibilidades. Cardiologia e Saúde Pública 9:201-209,1993. [ Links ]
7. Dutra WO, Martins OA, Cançado JR, Dias JCP, Brener Z, Freeman GL, Colley DG, Gazinelli G, Parra JC. Activated T and B lymphocytes in peripheral blood of patients with Chagas' disease. Internal Immunology 6:499-506, 1994. [ Links ]
8. Dutra WO, Martins-Filho OA, Cançado JR, Dias JCP, Brener Z, Gazzinelli G, Carvalho JF, Colley DG. Chagasic patients lack CD28 expression on many of their circulating T lymphocytes. Scandinavian Journal of Immunology 43:88-93, 1996. [ Links ]
9. Dutra WO, Gollob KJ, Dias JCP, Gazzinelli G, Oliveira RLC, Coffman RL, Parra JFC. Cytokine mRNA profile of peripheral blood mononuclear cells isolated from individuals with Trypanosoma cruzi chronic infection. Journal of Immunology 45:74-80, 1997. [ Links ]
10. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH. Tumor necrosis factor and interleukin 1 in the serum of children with severe infectious purpura. New England Journal of Medicine 319:397-400, 1988. [ Links ]
11. Hall BF, Joiner KA. Strategies of obligate intracellular parasites for evading host defenses. Immunology Today 12:A22-A2, 1991. [ Links ]
12. Higuchi ML. Chronic chagasic cardiopathy: the product of a turbulent host-parasite relationship. Revista do Instituto de Medicina Tropical 39: 53-60, 1997. [ Links ]
13. Hodt DF, Lynch RG, Kirchoff LV. Kinetic analysis of antigen-specific immune response in resistant and susceptible mice during infection with Trypanosoma cruzi. Journal of Immunology 151:7038-7047, 1993. [ Links ]
14. Humphrey JS, McCormick Mc, Rowland EC. Parasite antigen-induced IFN-gamma and IL-4 production by cells from pathopermissive and pathoresistant strains of mice infected with Trypanosoma cruzi. Journal of Parasitology 83:533-536, 1997. [ Links ]
15. Kierszembaum F, Mejia L H, Sztein MB. Does interleukin-2 restore lymphocyte responses suppressed by Trypanosoma cruzi? Immunology 80:445-450, 1993. [ Links ]
16. Kirchoff LV. American trypanosomiasis (Chagas' disease) - a tropical disease now in the United States. New England Journal of Medicine 329:639-643, 1993. [ Links ]
17. Mady C, Nacruth R. História natural da cardiopatia chagásica crônica: fatores prognósticos. Revista da Sociedade de Cardiologia de São Paulo 2:124-128, 1994. [ Links ]
18. Miller MJ, Wrightsman RA, Manning JE. Trypanosoma cruzi: protective immunity in mice immunized with paraflagelar rod proteins is associated with a T-helper type 1 response. Experimental Parasitology 84:156-167, 1996. [ Links ]
19. Moraes MDL, Minoprio P, Dy M, Dardenne M, Savino W, Hontebeyrie-Joskowicz M. Endogenous IL-10 and IFN-gamma production controls thymic cell proliferation in mice acutely infected by Trypanosoma cruzi. Scandinavian Journal of Immunology 39: 51-58, 1994. [ Links ]
20. Morato MJF, Colley DG, Powell MR. Cytokine profiles during experimental Chagas' disease. Brazilian Journal of Medical Research 31:123-125, 1998. [ Links ]
21. Ramadori G, Van Damme J, Rieder H, Meyer BKH. Interleukin 6, the third mediator of acute phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor alpha. European Journal of Immunology 18:1259-1264, 1988. [ Links ]
22. Rossi MA, Bestetti RB. Hipótese unificada sobre a patogênese da cardiopatia chagásica crônica. Implicações terapêuticas. Arquivos Brasileiros de Cardiologia 64:255-261, 1995. [ Links ]
23. Stracieri ABPL, Voltarelli JC. NK and LAK functions in human chronic Chagas disease. Parasite Immunology 17:381-383, 1995. [ Links ]
24. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/tumor necrosis factor monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664, 1987. [ Links ]
25. Vandekerckhove F, Darji A, Rivera MT, Carlier Y, Vray B, Billiau A, Baetselier P. Modulation of T-cell responsiveness during Trypanosoma cruzi infection: analysis in different lymphoid compartments. Parasite Immunology 16:77-85, 1994. [ Links ]
26. Voltarelli JC, Donadi EA, Falcão RP. Immunossupression in human acute Chagas' disease. Transactions of the Royal Society of Tropical Medicine and Hygiene 81:169-170, 1987. [ Links ]
27. Waage A, Halstensen A, Espevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1:355-357, 1987. [ Links ]
28. World Health Organization. Control of Chagas' disease. Report a WHO Expert Committee. Geneva. WHO Technical Report Series 811:1-95, 1991. [ Links ]
29. Zhang L, Tarleton RL. Persistent production of inflammatory and anti-inflammatory cytokines and associated MHC and adhesion molecule expression at the site of infection and disease in experimental Trypanosoma cruzi infections. Experimental Parasitology 84:203-213, 1996. [ Links ]
1. Department of Medicine, Divisions of Internal Medicine and 2. Clinical Pathology - Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, SP, Brazil and 3. Department of Medicine, Division of Endocrinology - Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.
This work was supported, in part, by grants from FAPESP and CNPq-Brasil.
Address to: Drª Laura Sterian Ward. Med. Int./Semio. Clín. Med./FCM. Cidade Universitária Zeferino Vaz, 13081-970 Campinas, SP, Brasil.
Telefax: 55 19 2894107.
Recebido para publicação em 21/5/98.